Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 8Neoplasms 4Multiple Myeloma 3Radiation Injuries 2Multiple Chronic Conditions 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Esophageal Neoplasms 2Cognitive Dysfunction 2Brain Neoplasms 2Substance-Related Disorders 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Pain 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms, Plasma Cell 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mobility Limitation 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Hyperthermia 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Ultrasonic Waves 1Tobacco Use Cessation Devices 1Therapeutics 1Surveys and Questionnaires 1Patient Reported Outcome Measures 1Nicotine Replacement Therapy 1Nicotine Chewing Gum 1Ethanol 1Educational Status 1Dosage Forms 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Substance-Related Disorders × Patient Reported Outcome Measures × Clear all
NCT05684939 2023-06-13

CAPS

University Hospital, Clermont-Ferrand

Completed
2,010 enrolled

Neoplasms, Pain, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡